1. Jin, H.G. and Gao, L.X. (2016) Advances in the Treatment of Rheumatic Immune Diseases with Biological Agents. Clinical Metabolism, 31, 490-495.
2. Gao, L.X., Ma, L.Y., et al. (2019) Main Clinical Progress of Rheumatology in 2018. Clinical Metadata, 34, 23-32.
3. Lu, Y.J. (2020) The Application Value of Biological Agents in Rheumatism Immunotherapy. Contemporary Medicine, 26, 75-77.
4. Pan, T., Zhu, A.L., Guo, F., et al. (2018) To Study the Clinical Efficacy of Yisaipu in Patients with Rheumatic Immune Diseases. China Practical Medicine, 13, 103-105.
5. The National Medical Security Administration (2019) The National Medical Security Administration and Other Nine Departments on the Implementation of the National Organization of the Pilot Program of Centralized Procurement and Use of Drugs to Expand the Scope of the Implementation. http://www.nhsa.gov.cn/art/2019/9/30/art_37_1817.html